Drug Type Small molecule drug |
Synonyms- |
Target |
Action inhibitors, antagonists |
Mechanism G6PD inhibitors(Glucose-6-phosphate 1-dehydrogenase inhibitors), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization- |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC26H34O6 |
InChIKeySCULJPGYOQQXTK-OLRINKBESA-N |
CAS Registry470-37-1 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hepatocellular Carcinoma | Preclinical | China | 26 May 2025 | |
| Diffuse Large B-Cell Lymphoma | Preclinical | China | 14 May 2024 |





